
Corporate
ImmunityBio Stock Surges 83% as Cancer Drug Anktiva Posts 700% Revenue Growth
4d ago
You're signed outSign in or to get full access.
View earnings summary and analysis
View earnings summary and analysis
View earnings summary and analysis
View earnings summary and analysis
Research analysts covering ImmunityBio.